Cancer patients as well as patients with conditions such as cystic fibrosis and chronic pancreatitis are now confronted with an acute shortage of an essential medication—Creon. This pancreatic enzyme replacement therapy (PERT) is crucial to digesting food, one of the most fundamental of human activities which becomes all but impossible for those with pancreatic insufficiency.The consequences are frightening- patients are forgoing meals, dividing up doses, and driving more than 30 miles just to receive the capsules. The effect is not just nutritional but life-threatening, because not being able to properly digest food can make a person vulnerable to infection, make them weaker, and restrict access to life-saving treatment like chemotherapy.Creon is the brand name of pancreatic enzyme replacement therapy that is used to manage exocrine pancreatic insufficiency (EPI)—a disease in which the pancreas is unable to produce enzymes to help digest food. This inability can be due to a variety of reasons, such as pancreatic cancer, cystic fibrosis, chronic pancreatitis, and complications after surgery like gastric-bypass or pancreatic surgery.For individuals with EPI, Creon® is not merely a supportive therapy—it is a lifeline. It allows them to extract nutrition from food and sustain body weight, energy, and immune capacity. Without it, patients experience persistent diarrhea, abdominal pain, malnutrition, and ultimately, reduced quality of life and survivability.The Government in the UK has prolonged the Serious Shortage Protocol (SSP) for Creon until November 2025, enabling pharmacists to dispense a reduced quantity without a fresh prescription. Although the policy tries to make things more accessible, this is a short-term solution to an ongoing and hazardous shortage.One survey carried out by the National Pharmacy Association (NPA), surveying more than 300 pharmacies, shows a dire picture. A whopping 96% of these pharmacies are struggling to get Creon, the essential pancreatic enzyme replacement therapy. Additionally, 89% have the same shortages with other drugs like Nutrizym and Pancrex. This shortage is making many patients go distances of over 30 miles just to get a pharmacy that will fill their prescriptions. Even more alarming, many patients are said to be skipping meals or cutting their doses in order to stretch their short supplies, jeopardizing their health and wellbeing in the process.The shortage is primarily due to "European-wide supply issues" and production limitations on the drug that have caused interruptions in the manufacture and distribution of Creon, as reported by the Department of Health and Social Care. The interruptions are not specific to Creon but point to systemic weaknesses in pharmaceutical production.In Creon's case, though, the end result is worse. Unlike certain drugs that can be skipped or substituted for others, Creon® is instantly vital with each patient meal. There is no "respite" from taking it, and even temporary discontinuation can cause health emergencies.How is the Shortage of the Drug Affecting Cancer Patients?The psychological and physical strain on the patients cannot be estimated. As Alfie Bailey-Bearfield, Pancreatic Cancer UK's Head of Influencing & Health Improvement, stressed, "It's completely unacceptable that they are still taking desperate steps which risk their health, wellbeing, and their suitability for treatment."Patients going without meals in order to cut corners on enzyme capsules put themselves at significant risk of malnutrition and severe weight loss. Not only does this compromise the immune response of the body, it lowers tolerance to chemotherapy, effectively excluding patients from life-sustaining or curative therapy. The medical risk is not abstract—it's real and measurable.What is EPI?Exocrine Pancreatic Insufficiency (EPI) is more prevalent than many people know. In the UK alone, approximately 61,000 patients need pancreatic enzyme therapy. Reasons are:Pancreatic cancer (especially advanced)Cystic fibrosisChronic and acute pancreatitisPancreatic surgery or gastric bypassUntreated celiac disease or inflammatory bowel diseaseEPI results in undigested food entering the colon, leading to bloating, gas, cramps, and diarrhea. With time, the nutrient deficiencies cause weight loss, bone loss, and even increased cardiovascular risk. In children, it impairs growth and development.Unlike regular prescriptions, Creon is not prescribed with a set amount. It has to be individualized for each patient, for each meal, and even for each snack. The dosing is 3,000 to 36,000 enzyme units per capsule. For comparison, a normal pancreas will release up to 720,000 units for a small meal.Patients are instructed to self-regulate according to their intake, so that a consistent and plentiful source becomes not only the preferred but also the necessary mode of correct dosing. Under shortages, this individualized dosing is a luxury many cannot enjoy.Healthcare providers and patient advocacy groups alike are demanding immediate government action. Bailey-Bearfield and Picard have issued public calls for a strategic restructuring to solve manufacturing constraints and enhance distribution systems."This crisis continues to put people's health at risk, and they cannot afford to wait any longer," Bailey-Bearfield implored.It takes not only stockpiling but also long-term planning, such as investment in alternative manufacturing hubs, local production incentives, and better global supply chain coordination.